Edesa Biotech, Inc. (EDSA)

Pharmaceutical Preparations · market cap $38M · as of 2026-07-15

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

None scheduled

Pipeline

programs

Upcoming events

next 90d+

Dossier

Ready

cached

Edesa Biotech (EDSA) is a micro-cap clinical-stage pharmaceutical company with 17 employees and a $61M market cap, built around a single Phase 2 asset: EB01 Cream 0.2% for Allergic Contact Dermatitis. The company holds $10M in cash (~7.3 months runway) and carries no revenue, making near-term financing essentially inevitable. The next scheduled event is an earnings release on 2026-08-14.

The catalyst path

No upcoming catalysts in our calendar.

Pipeline

Asset	Phase	Indication
EB01 Cream 0.2%	Phase 2	Allergic Contact Dermatitis

Price & technical context

3-month

-45.7%

6-month

-19.5%

12-month

+71.8%

52-wk range

$0.80–$18.27

vs 50-day MA

-11.9%

vs 200-day MA

-23.2%

Realized vol

166.1%

Max drawdown

-82.9%

Daily closes through 2026-09-30. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

Sources & data

SEC filings — EDGAR filings for EDSA (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 1 registered trial on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.